Carotid sparing intensity-modulated radiation therapy achieves comparable locoregional control to conventional radiotherapy in T1-2N0 laryngeal carcinoma. Issue 7 (July 2015)

• Record Type: Journal Article
• Authors: Zumsteg, Zachary S.; Riaz, Nadeem; Jaffery, Sana; Hu, Man; Gelblum, Daphna; Zhou, Ying; Mychalczak, Borys; Zelefsky, Michael J.; Wolden, Suzanne; Rao, Shyam; Lee, Nancy Y.
• Is Part Of: Oral oncology. Volume 51:Issue 7(2015:Jul.)
• Page Start: 716
• Page End: 723
• Publication Date: 2015-07
• Subjects: Mouth -- Cancer -- Periodicals; Mouth -- Tumors -- Periodicals; Mouth Diseases -- Periodicals; Mouth Neoplasms -- Periodicals; Bouche -- Cancer -- Périodiques; Bouche -- Tumeurs -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9943105
• DOI: 10.1016/j.oraloncology.2015.02.003
• Languages: English
• ISSNs: 1368-8375

Abstract

<abstract xml:lang="en" abstract-type="author" id="ab005"> <title id="st055">Summary</title> <sec> <title id="st060">Background</title> <p id="sp0005">Although intensity-modulated radiotherapy (IMRT) is a standard of care for many head and neck cancers, its use for carotid-sparing (CS) therapy in early-stage laryngeal carcinoma is controversial.</p> </sec> <sec> <title id="st065">Methods</title> <p id="sp0010">330 consecutive patients with early-stage laryngeal carcinoma were treated from 1/1989 to 5/2011, including 282 conventional radiotherapy (CRT) and 48 CS-IMRT patients. The median follow-up was 43 (CS-IMRT) and 66 (CRT) months.</p> </sec> <sec> <title id="st070">Results</title> <p id="sp0015">There was no difference in local failure rates comparing patients undergoing CS-IMRT with CRT, with 3-year local control rates of 88% vs. 89%, respectively (<italic>p</italic> = 0.938). Using a 1 cm circumferential margin, the average dose to the left and right carotid arteries was 48.3 and 47.9 Gy, respectively. 88% of locoregional recurrences involved the ipsilateral true vocal cord, including all local recurrences in the IMRT group.</p> </sec> <sec> <title id="st075">Conclusions</title> <p id="sp0020">These results warrant further prospective evaluation of CS-IMRT for early-stage glottic larynx cancer.</p> </sec> </abstract>